BrainCool AB, a Swedish medical device innovator, and a world leader in medical cooling technology for therapeutic hypothermia (brain cooling) and oncology, is pleased to announce that it has completed patient recruitment in the Scandinavian multi-center pivotal trial of 180 patients to investigate the patented Cooral ® System for prevention of Oral Mucositis (OM), one of the most debilitating side-effects of both standard and high-dose chemotherapeutic oncology treatments.
In the United States (U.S.), BrainCool is conducting a De Novo 510 k regulatory process, with the aim of obtaining product and market clearance for the Cooral ® System in the U.S. by the Food and Drug Administration (FDA). The De Novo process was introduced by the FDA for instances where a device is novel and there is therefore no suitable predicate device to support a standard 510(k) submission. To qualify for the De Novo pathway, the new device must also present no more than moderate risk.
BrainCool has been granted FDA "Expedited Access Pathway" (EAP) status and will be given priority review for the Cooral ® System. EAP projects address unmet medical needs for life threatening or irreversibly debilitating diseases or conditions that are subject to premarket approval applications (PMA), or are eligible for de novo requests.
With full patient recruitment for our pivotal trial, we are opening an important new door in cancer care and treatment. Conclusive validation that cryotherapeutic intervention with the Cooral ® System can safely and effectively prevent the excruciating side-effects of oral mucositis is not just a major medical milestone, it's actually a matter of life and death." Martin Waleij, CEO BrainCool AB Related Stories
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology